Outcomes and Clinical Progression of COVID-19 in Hematopoietic Cell Transplant Patients
Overview
This regional Middle East study analyzed 91 hematopoietic cell transplant (HCT) recipients who developed COVID-19, revealing a median age of 35 years and a median 14.9 months from transplant to infection. The study assessed COVID-19 severity, clinical outcomes, and risk factors impacting disease progression in this immunocompromised population.
Background
COVID-19, caused by SARS-CoV-2, emerged in late 2019 and rapidly became a global pandemic with significant morbidity and mortality. Patients undergoing hematopoietic cell transplantation (HCT) are considered vulnerable due to immunosuppression and frequent lung complications post-transplant. Understanding COVID-19 outcomes in HCT recipients is critical to optimize management and improve prognosis. This study retrospectively reviewed cases from ten Middle East centers to characterize clinical progression and identify risk factors influencing severity.
Data Highlights
Characteristic
Value
Number of patients
91
Median age (years)
35
Median time from transplant to COVID-19 (months)
14.9 (IQR 16.3–38.9)
Gender distribution
42% female, 58% male
Type of transplant
57% allogeneic, 43% autologous
Patients on immunosuppression
52%
Patients with comorbidities
48%
Symptomatic at diagnosis
86%
Most common symptoms
Fever (56%), cough (41%), shortness of breath (24%)
Chest X-ray abnormality rate
58% of those imaged
Patients receiving COVID-19 directed therapy
48%
Key Findings
Median age of HCT patients with COVID-19 was 35 years, with a median 14.9 months from transplant to infection.
52% of patients were on immunosuppressive medications at COVID-19 diagnosis.
48% of patients had prior comorbidities, with 34% of those having multiple comorbidities.
86% of patients were symptomatic at diagnosis; fever, cough, and shortness of breath were the most frequent symptoms.
Chest X-rays were abnormal in 58% of patients who underwent imaging, indicating pulmonary involvement.
COVID-19 directed therapies were administered in 48% of cases, reflecting varied treatment approaches.
Clinical Implications
HCT recipients represent a high-risk group for COVID-19 with frequent symptomatic presentation and pulmonary involvement. Close monitoring and early intervention are warranted, especially for those on immunosuppression or with comorbidities. Tailored therapeutic strategies should be considered to mitigate severe outcomes in this vulnerable population.
Conclusion
This regional analysis highlights the clinical characteristics and outcomes of COVID-19 in HCT patients, emphasizing the importance of vigilant care and risk stratification to improve prognosis. Further studies are needed to refine management protocols in this immunocompromised group.
by Riad El Fakih, Alfadil Haroon, Feras Alfraih, Murtadha K. Al-Khabori, Mohsen Alzahrani, Ahmad Alhuraiji, Abdulaziz Hamadah, Naif I. AlJohani, Bader Alahmari, Mohammed F. Essa, Ibraheem H. Motabi, Imran K. Tailor, Reem S. Almaghrabi, Khalil Al-Farsi, Ibraheem Abosoudah, Mouhab Ayas, Tusneem A. Elhassan, Ashraf M. Suhebeh, Syed Osman Ahmed, Saud Alhayli, Panayotis Kaloyannidis, Ahmad Alsaeed, Khalid Al Anezi, Sameer Alamoudi, Moussab Damlaj, Hani Al Hashmi, Mahmoud Aljurf
